Unraveling the safety and efficacy of semaglutide for people living with HIV and metabolic co-morbidities

Affiliations

¹ Second Propedeutic Department of Internal Medicine, Faculty of Medicine, School of Health Sciences Aristotle, University of Thessaloniki, Thessaloniki, Greece.
² Second Department of Cardiology, Faculty of Medicine, School of Health Sciences Aristotle, University of Thessaloniki, Thessaloniki, Greece.
³ Department of Endocrinology, Riga East Clinical University Hospital, Riga, Latvia.
⁴ Pharmacy, Ras Al Khaimah Medical and Health Sciences University (RAKMHSU), RAK, United Arab Emirates.
⁵ School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, Italy.

Editorial

Dimitrios Patoulias et al. Expert Opin Drug Saf. 2025 Feb.

. 2025 Feb;24(2):121-124.

doi: 10.1080/14740338.2024.2435426. Epub 2024 Nov 28.

¹ Second Propedeutic Department of Internal Medicine, Faculty of Medicine, School of Health Sciences Aristotle, University of Thessaloniki, Thessaloniki, Greece.
² Second Department of Cardiology, Faculty of Medicine, School of Health Sciences Aristotle, University of Thessaloniki, Thessaloniki, Greece.
³ Department of Endocrinology, Riga East Clinical University Hospital, Riga, Latvia.
⁴ Pharmacy, Ras Al Khaimah Medical and Health Sciences University (RAKMHSU), RAK, United Arab Emirates.
⁵ School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, Italy.

No abstract available

Keywords: HIV; cardiovascular disease; dysmetabolism; obesity; semaglutide.

Publication types